# A Study to Learn About the Study Medicine Called Ponsegromab in Adults With Lung Cancer-Associated Significant Body Weight Loss

> **NCT07663630** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Pfizer** · enrollment: 80 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer (NSCLC)
- Cachexia

## Interventions

- **DRUG:** ponsegromab
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT07663630
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-23
- **Primary completion:** 2028-05-06
- **Final completion:** 2029-07-01
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07663630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07663630, "A Study to Learn About the Study Medicine Called Ponsegromab in Adults With Lung Cancer-Associated Significant Body Weight Loss". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07663630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*